Skip to main content
HR 1344 116th Congress House Health Administrative remedies Business expenses Civil actions and liability Competition and antitrust Federal Trade Commission (FTC) Income tax deductions Intellectual property Judicial review and appeals Marketing and advertising Prescription drugs Research and development Tax administration and collection, taxpayers

Competitive DRUGS Act of 2019

Introduced: February 25, 2019 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 25, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Feb 26, 2019
Referred to the Subcommittee on Health.
Feb 25, 2019
Referred to the Committee on Ways and Means, and in addition to the Committees on Energy and Commerce, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 25, 2019
Referred to the Subcommittee on Health.
Feb 25, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 or the Competitive DRUGS Act of 2019

This bill authorizes the Federal Trade Commission to initiate a proceeding against parties to an agreement resolving or settling a patent infringement claim in connection with the sale of a drug. Such an agreement is generally presumed to be an unfair method of competition and is a violation of this bill if the filer of the generic drug application receives something of value and agrees to limit or forgo research, development, manufacturing, marketing, or sales of the generic drug.

However, an agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market the generic drug prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on a claim that the generic drug infringes a patent. An agreement if also exempt if the agreement's pro-competitive benefits outweigh its anticompetitive effects.

The bill establishes penalties for violations of the bill.

What's happening now March 25, 2019

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

 Related & companion bills 2
  • HR 2375 Related bill Preserve Access to Affordable Generics and Biosimilars Act
  • S 64 Related bill Preserve Access to Affordable Generics and Biosimilars Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 6
 Cosponsors 14
All 14 Democratic 13
D
Garamendi, John
California · Feb 26, 2019
 D
Chu, Judy
California · Feb 25, 2019
CUMMINGS, ELIJAH
· Feb 25, 2019
 D
DeLauro, Rosa L.
Connecticut · Feb 25, 2019
 D
DeSaulnier, Mark
California · Feb 25, 2019
 D
Kaptur, Marcy
Ohio · Feb 25, 2019
 D
Khanna, Ro
California · Feb 25, 2019
 D
Moore, Gwen
Wisconsin · Feb 25, 2019
 D
Norton, Eleanor Holmes
District of Columbia · Feb 25, 2019
 D
Ocasio-Cortez, Alexandria
New York · Feb 25, 2019
 D
Pingree, Chellie
Maine · Feb 25, 2019
 D
Pocan, Mark
Wisconsin · Feb 25, 2019
 D
Waters, Maxine
California · Feb 25, 2019
 D
Welch, Peter
Vermont · Feb 25, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1344: Competitive DRUGS Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-1344/
MLA
"H.R. 1344: Competitive DRUGS Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-1344/.
Bluebook (legal)
H.R. 1344, 116th Cong. (2026), https://openamerica.io/bill/116-HR-1344/.
Markdown link
[H.R. 1344: Competitive DRUGS Act of 2019](https://openamerica.io/bill/116-HR-1344/)
Report a problem